Fate of tritiated Didemnin B in mice: Excretion and tissue concentrations after an intraperitoneal dose

Val R. Beasley, Sally J. Bruno, John S. Burner, Byoung W. Choi, Kenneth L. Rinehart, Gary D. Koritz, Jeffrey M. Levengood

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Didemnin B has undergone trials in cancer patients, and has antiviral and immunosuppressive properties. [3H]didemnin B was administered intraperitoneally (i.p.) to mice at 320 or 1280 μg/kg. Urine and feces were collected until 168 h, at which time the mice were killed and tissues collected. Additionally, [3H]didemnin B was given i.p. at 320 μg/kg, and mice were killed at 1-120 h post-dosing. Radiolabel increased rapidly in blood then rapidly declined. Most radiolabel in urine, feces and tissues represented parent compound. Concentrations of [3H]didemnin B were greatest in the liver > gallbladder > lower digestive tract ≅ pancreas > spleen > kidney ≅ adipose tissue ≅ urinary bladder with urine. The pancreas had the longest terminal half-life of the tissues and the highest radioactivity at 7 days. Intermediate concentrations were in the duodenum ≅ jejunum > lung > iliopsoas > stomach ≅ testes ≅ skin > heart. Low concentrations were in the humerus ≅ femur ≅ quadriceps ≅ triceps ≫ brain. Fecal excretion accounted for 45.9%-58.3% of the dose and declined after 24 h, followed by an increase, suggesting possible enterohepatic recycling or an impact of circadian rhythms. Urinary excretion accounted for 18.4%-25.2% of the dose, but was minimal after 24 h. The concentrations were highest in organs previously found to be sensitive in animals and humans. Didemnin B should be evaluated in animal models for treatment of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)341-351
Number of pages11
JournalBiopharmaceutics and Drug Disposition
Issue number8
StatePublished - Nov 2005

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)


Dive into the research topics of 'Fate of tritiated Didemnin B in mice: Excretion and tissue concentrations after an intraperitoneal dose'. Together they form a unique fingerprint.

Cite this